fleroxacin has been researched along with Pneumonia in 5 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
Pneumonia: Infection of the lung often accompanied by inflammation.
Excerpt | Relevance | Reference |
---|---|---|
"Fleroxacin, administered intravenously at a dosage of 400 mg once a day, was compared with ceftazidime, 0." | 6.67 | Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections. ( Farkas, SA, 1993) |
" Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L." | 5.28 | In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ( Edelstein, MA; Edelstein, PH; Holzknecht, B, 1992) |
"Fleroxacin, administered intravenously at a dosage of 400 mg once a day, was compared with ceftazidime, 0." | 2.67 | Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections. ( Farkas, SA, 1993) |
" Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L." | 1.28 | In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ( Edelstein, MA; Edelstein, PH; Holzknecht, B, 1992) |
"Fleroxacin was inactive against S." | 1.28 | In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. ( Beskid, G; Chan, K; Cleeland, R; Keith, DD; McGarry, CM; Siebelist, J, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jones, RN | 1 |
Erwin, ME | 1 |
Hager, HL | 1 |
Hohl, PE | 1 |
Farkas, SA | 1 |
Edelstein, PH | 1 |
Edelstein, MA | 1 |
Holzknecht, B | 1 |
Beskid, G | 1 |
Siebelist, J | 1 |
McGarry, CM | 1 |
Cleeland, R | 1 |
Chan, K | 1 |
Keith, DD | 1 |
Hirai, K | 1 |
Aoyama, H | 1 |
Hosaka, M | 1 |
Oomori, Y | 1 |
Niwata, Y | 1 |
Suzue, S | 1 |
Irikura, T | 1 |
1 trial available for fleroxacin and Pneumonia
Article | Year |
---|---|
Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacteria; Bronchitis; Ceftazidime; Female; Fleroxacin | 1993 |
4 other studies available for fleroxacin and Pneumonia
Article | Year |
---|---|
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.
Topics: Bacteria; Bronchitis; Clinical Trials as Topic; Europe; False Positive Reactions; Fleroxacin; Humans | 1993 |
In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Fleroxacin; Guinea Pigs; Legionella pneumophila; Legionnaires' Disease; Macrophages, Alveol | 1992 |
In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Drug Evaluation, Pr | 1990 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |